MedTrace Logo

Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)

NCT05475171 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2026-05-22

No results posted yet for this study

Summary

To learn if MGD019 can help to control cervical cancer in patients who have yet to receive treatment.

Conditions

Interventions

DRUG

Lorigerlimab

Given by vein (IV)

Sponsors & Collaborators

  • MacroGenics

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Amir Jazeri, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-13
Primary Completion
2026-06-30
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05475171 on ClinicalTrials.gov